Web based Drug Database (1.07 Linux)

NABUMETONE

Names
Common Name	NABUMETONE
Other Name	NABUMETONE
Pharmacological Group	NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
Chemical Name	4-(6-Methoxy-2-naphthyl)butan-2-one
Chemical Group

Attributes

Indications	Contraindications	Prescriber Cautions	Patient Cautions
Toxicity	Side Effects	Liver Disease	Renal Failure
Pregnancy	Lactation	Pharmacological Actions	Diagnostic Procedures
Drugs	Interactions

Indications

Gout
Rheumatoid arthritis

Contraindications

Asthma
Peptic ulcer
Analgesic allergy
Chronic asthmatic bronchitis
Peptic ulcer of oesophagus
Gastric ulcer
Duodenal ulcer
Peptic ulcer - (PU) site unspecified
Gastrojejunal ulcer
Gastritis and duodenitis
Adverse reaction to antirheumatics
Airways obstruction reversible
Non-steroidal anti-inflammatory drugs contraindicated

Prescriber Cautions

Consult current official advice regarding NABUMETONE

Patient Cautions

See information on products containing NABUMETONE for specific advice for patients

Toxicity

- None Listed -

Side Effects

Nephrotic syndrome - Rare
Renal function tests abnormal - Rare
Acute hepatic failure - Very Rare
Jaundice - Very Rare
Leucopenia - Very Rare
Liver function tests abnormal - Very Rare
Stevens-Johnson syndrome - Very Rare
Thrombocytopenia - Very Rare
Toxic epidermal necrolysis - Very Rare
Abdominal pain
Acute gastritis
Angioneurotic oedema
Black faeces
Bronchospasm
Confusion
Constipation
Depression
Diarrhoea
Dizziness
Drowsiness
Dry mouth
Dyspepsia
Excessive flatulence
Fatigue/asthenia
Gastrointestinal haemorrhage
Haematemesis
Hallucinations
Headache
Insomnia
Itching
Malaise/lethargy
Menorrhagia
Nausea
Oedema
Oral aphthae
Paraesthesia
Patches of alopecia
Peptic ulcer symptoms
Perforation of intestine
Photosensitiveness
Rash
Tinnitus
Visual symptoms
Vomiting

Liver Disease

Avoid NABUMETONE in severe liver disease
NABUMETONE causes sodium and water retention in liver disease
NABUMETONE - increased risk of gastrointestinal bleeding in liver disease

Renal Failure

Avoid NABUMETONE if possible in mild renal failure
Manufacturer advises reduce dose of NABUMETONE in renal failure
NABUMETONE - reduces renal function in renal failure
NABUMETONE - sodium and water retention in renal failure

Pregnancy

With regular doses of NABUMETONE - increased risk of closure of fetal ductus arteriosus in utero & possible persistent pulmonary hypertension of the newborn
Delayed onset & increased duration of labour with increased blood loss
Avoid NABUMETONE in the 1st TRIMESTER of pregnancy
Avoid NABUMETONE in the 3rd TRIMESTER of pregnancy
Manufacturer advises toxicity of NABUMETONE in pregnancy in animal studies

Lactation

Manufacturer advises insufficient information available about NABUMETONE in breast feeding
Manufacturers advise that mothers should not breast feed during treatment with NABUMETONE

Pharmacological Actions

ANALGESIC effect
ANTIINFLAMMATORY effect
ANTIPYRETIC effect
CYCLOOXYGENASE INHIBITOR effect
Preferential CYCLOOXYGENASE-2 INHIBITOR effect

Diagnostic Procedures

- None Listed -

Drugs containing NABUMETONE

RELIFEX 500mg tablets
NABUMETONE 500mg tablets
RELIFEX 500mg/5mL suspension
NABUMETONE 500mg/5mL susp

Interacting Ingredients

ACECLOFENAC
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of ACECLOFENAC. Moderate risk. May need to avoid combination
ACEMETACIN
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of ACEMETACIN. Moderate risk. May need to avoid combination
ALOXIPRIN
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of ALOXIPRIN. Moderate risk. May need to avoid combination
AMINOPHYLLINE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of AMINOPHYLLINE. Moderate risk. Avoid
ASPIRIN
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of ASPIRIN. Moderate risk. May need to avoid combination
ASPIRIN [RECTUM]
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of ASPIRIN [RECTUM]. Moderate risk. May need to avoid combination
AZAPROPAZONE
Likely interaction of AZAPROPAZONE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
BAMBUTEROL HYDROCHLORIDE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of BAMBUTEROL HYDROCHLORIDE. Moderate risk. Avoid
BECLOMETASONE [INHALED]
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of BECLOMETASONE [INHALED]. Moderate risk. Avoid
BENORILATE
Likely interaction of BENORILATE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
BETAMETHASONE
Likely interaction of BETAMETHASONE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. Monitor
BETAMETHASONE [INHALED]
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of BETAMETHASONE [INHALED]. Moderate risk. Avoid
BISMUTH CHELATE
Likely interaction of NABUMETONE reducing the ULCER HEALING effect of BISMUTH CHELATE. Moderate risk. Avoid
BUDESONIDE [GASTROINTESTINAL]
Likely interaction of BUDESONIDE [GASTROINTESTINAL] increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. Monitor
BUDESONIDE [INHALED]
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of BUDESONIDE [INHALED]. Moderate risk. Avoid
BUFYLLINE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of BUFYLLINE. Moderate risk. Avoid
CANDESARTAN CILEXETIL
Likely interaction of NABUMETONE increasing the NEPHROTOXICITY of CANDESARTAN CILEXETIL. Potential risk. Monitor
CARBENOXOLONE
Likely interaction of NABUMETONE reducing the ULCER HEALING effect of CARBENOXOLONE. Moderate risk. Avoid
CHOLINE MAGNESIUM TRISALICYLATE
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of CHOLINE MAGNESIUM TRISALICYLATE. Moderate risk. May need to avoid combination
CHOLINE THEOPHYLLINATE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of CHOLINE THEOPHYLLINATE. Moderate risk. Avoid
CIMETIDINE
Likely interaction of NABUMETONE reducing the ULCER HEALING effect of CIMETIDINE. Moderate risk. Avoid
CLOPIDOGREL
Theoretical potential for NABUMETONE increasing the PLATELET ANTAGONIST effect of CLOPIDOGREL. Moderate risk. May need to avoid combination
CORTISONE ACETATE
Likely interaction of CORTISONE ACETATE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. Monitor
CROMOGLICATE [INHALED]
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of CROMOGLICATE [INHALED]. Moderate risk. Avoid
DANAPAROID SODIUM
Theoretical potential for NABUMETONE increasing the ANTICOAGULANT effect of DANAPAROID SODIUM. Moderate risk. May need to avoid combination
DEGLYCYRRHIZINISED LIQUORICE
Likely interaction of NABUMETONE reducing the ULCER HEALING effect of DEGLYCYRRHIZINISED LIQUORICE. Moderate risk. Avoid
DEXAMETHASONE [ORAL]
Likely interaction of DEXAMETHASONE [ORAL] increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. Monitor
DEXAMETHASONE [PARENTERAL]
Likely interaction of DEXAMETHASONE [PARENTERAL] increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. Monitor
DEXIBUPROFEN
Likely interaction of DEXIBUPROFEN increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
DEXKETOPROFEN
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of DEXKETOPROFEN. Moderate risk. May need to avoid combination
DICLOFENAC POTASSIUM
Likely interaction of DICLOFENAC POTASSIUM increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [ORAL]
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of DICLOFENAC SODIUM [ORAL]. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [PARENTERAL]
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of DICLOFENAC SODIUM [PARENTERAL]. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [RECTUM]
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of DICLOFENAC SODIUM [RECTUM]. Moderate risk. May need to avoid combination
DIFLUNISAL
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of DIFLUNISAL. Moderate risk. May need to avoid combination
DIPROPHYLLINE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of DIPROPHYLLINE. Moderate risk. Avoid
ENOXAPARIN
Likely interaction of NABUMETONE increasing the ANTICOAGULANT effect of ENOXAPARIN. Moderate risk. May need to avoid combination
EPHEDRINE HYDROCHLORIDE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of EPHEDRINE HYDROCHLORIDE. Moderate risk. Avoid
EPROSARTAN
Likely interaction of NABUMETONE increasing the NEPHROTOXICITY of EPROSARTAN. Potential risk. Monitor
ESOMEPRAZOLE
Likely interaction of NABUMETONE reducing the ULCER HEALING effect of ESOMEPRAZOLE. Moderate risk. Avoid
ETODOLAC
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of ETODOLAC. Moderate risk. May need to avoid combination
FAMOTIDINE
Likely interaction of NABUMETONE reducing the ULCER HEALING effect of FAMOTIDINE. Moderate risk. Avoid
FENBUFEN
Likely interaction of FENBUFEN increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
FENOPROFEN
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of FENOPROFEN. Moderate risk. May need to avoid combination
FENOTEROL HYDROBROMIDE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of FENOTEROL HYDROBROMIDE. Moderate risk. Avoid
FLUDROCORTISONE ACETATE
Likely interaction of FLUDROCORTISONE ACETATE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. Monitor
FLURBIPROFEN
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of FLURBIPROFEN. Moderate risk. May need to avoid combination
FLURBIPROFEN [RECTUM]
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of FLURBIPROFEN [RECTUM]. Moderate risk. May need to avoid combination
FLUTICASONE [INHALED]
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of FLUTICASONE [INHALED]. Moderate risk. Avoid
FONDAPARINUX SODIUM
Likely interaction of NABUMETONE increasing the ANTICOAGULANT effect of FONDAPARINUX SODIUM. Moderate risk. May need to avoid combination
FORMOTEROL
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of FORMOTEROL. Moderate risk. Avoid
HYDROCORTISONE
Likely interaction of HYDROCORTISONE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. Monitor
HYDROCORTISONE SODIUM PHOSPHATE
Likely interaction of HYDROCORTISONE SODIUM PHOSPHATE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. Monitor
HYDROCORTISONE SODIUM SUCCINATE
Likely interaction of HYDROCORTISONE SODIUM SUCCINATE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. Monitor
IBUPROFEN
Likely interaction of IBUPROFEN increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
IBUPROFEN LYSINE
Likely interaction of IBUPROFEN LYSINE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
INDACATEROL
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of INDACATEROL. Moderate risk. Avoid
INDOMETACIN
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of INDOMETACIN. Moderate risk. May need to avoid combination
INDOMETACIN [RECTUM]
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of INDOMETACIN [RECTUM]. Moderate risk. May need to avoid combination
IRBESARTAN
Likely interaction of NABUMETONE increasing the NEPHROTOXICITY of IRBESARTAN. Potential risk. Monitor
ISOETARINE HYDROCHLORIDE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of ISOETARINE HYDROCHLORIDE. Moderate risk. Avoid
ISOPRENALINE HYDROCHLORIDE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of ISOPRENALINE HYDROCHLORIDE. Moderate risk. Avoid
ISOPRENALINE SULPHATE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of ISOPRENALINE SULPHATE. Moderate risk. Avoid
KETOPROFEN
Likely interaction of KETOPROFEN increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
KETOPROFEN [RECTUM]
Likely interaction of KETOPROFEN [RECTUM] increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
KETOROLAC TROMETAMOL
Likely interaction of NABUMETONE increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
KETOTIFEN
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of KETOTIFEN. Moderate risk. Avoid
LANSOPRAZOLE
Likely interaction of NABUMETONE reducing the ULCER HEALING effect of LANSOPRAZOLE. Moderate risk. Avoid
LOSARTAN POTASSIUM
Likely interaction of NABUMETONE increasing the NEPHROTOXICITY of LOSARTAN POTASSIUM. Potential risk. Monitor
LYSINE ASPIRIN
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of LYSINE ASPIRIN. Moderate risk. May need to avoid combination
MEFENAMIC ACID
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
MELOXICAM
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of MELOXICAM. Moderate risk. May need to avoid combination
MELOXICAM [RECTUM]
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of MELOXICAM [RECTUM]. Moderate risk. May need to avoid combination
MESALAZINE
Theoretical potential for NABUMETONE increasing the NEPHROTOXICITY of MESALAZINE. Potential risk. May need to avoid combination
METHYLEPHEDRINE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of METHYLEPHEDRINE. Moderate risk. Avoid
METHYLPREDNISOLONE
Likely interaction of METHYLPREDNISOLONE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. Monitor
MIFEPRISTONE
Theoretical potential for NABUMETONE increasing the PROSTANERGIC effect of MIFEPRISTONE. Potential risk. Avoid
MONTELUKAST
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of MONTELUKAST. Moderate risk. Avoid
NAPROXEN
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
NAPROXEN SODIUM
Likely interaction of NAPROXEN SODIUM increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
NAPROXEN [RECTUM]
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of NAPROXEN [RECTUM]. Moderate risk. May need to avoid combination
NEDOCROMIL SODIUM
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of NEDOCROMIL SODIUM. Moderate risk. Avoid
NIZATIDINE
Likely interaction of NABUMETONE reducing the ULCER HEALING effect of NIZATIDINE. Moderate risk. Avoid
OLMESARTAN MEDOXOMIL
Likely interaction of NABUMETONE increasing the NEPHROTOXICITY of OLMESARTAN MEDOXOMIL. Potential risk. Monitor
OMEPRAZOLE [ORAL]
Likely interaction of NABUMETONE reducing the ULCER HEALING effect of OMEPRAZOLE [ORAL]. Moderate risk. Avoid
OMEPRAZOLE [PARENTERAL]
Likely interaction of NABUMETONE reducing the ULCER HEALING effect of OMEPRAZOLE [PARENTERAL]. Moderate risk. Avoid
ORCIPRENALINE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of ORCIPRENALINE. Moderate risk. Avoid
ORCIPRENALINE [INHALED]
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of ORCIPRENALINE [INHALED]. Moderate risk. Avoid
PANTOPRAZOLE
Likely interaction of NABUMETONE reducing the ULCER HEALING effect of PANTOPRAZOLE. Moderate risk. Avoid
PHENYLBUTAZONE
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of PHENYLBUTAZONE. Moderate risk. May need to avoid combination
PIRBUTEROL
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of PIRBUTEROL. Moderate risk. Avoid
PIROXICAM
Likely interaction of PIROXICAM increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
PIROXICAM [RECTUM]
Likely interaction of PIROXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
PIROXICAM-BETADEX
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of PIROXICAM-BETADEX. Moderate risk. May need to avoid combination
PREDNISOLONE
Likely interaction of PREDNISOLONE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. Monitor
PREDNISOLONE ACETATE
Likely interaction of PREDNISOLONE ACETATE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. Monitor
PREDNISOLONE SODIUM PHOSPHATE
Likely interaction of PREDNISOLONE SODIUM PHOSPHATE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. Monitor
PREDNISONE
Likely interaction of PREDNISONE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. Monitor
RABEPRAZOLE
Likely interaction of NABUMETONE reducing the ULCER HEALING effect of RABEPRAZOLE. Moderate risk. Avoid
RANITIDINE
Likely interaction of NABUMETONE reducing the ULCER HEALING effect of RANITIDINE. Moderate risk. Avoid
RANITIDINE BISMUTH CITRATE
Likely interaction of NABUMETONE reducing the ULCER HEALING effect of RANITIDINE BISMUTH CITRATE. Moderate risk. Avoid
REPROTEROL HYDROCHLORIDE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of REPROTEROL HYDROCHLORIDE. Moderate risk. Avoid
RIMITEROL HYDROBROMIDE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of RIMITEROL HYDROBROMIDE. Moderate risk. Avoid
RITODRINE HYDROCHLORIDE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of RITODRINE HYDROCHLORIDE. Moderate risk. Avoid
SALBUTAMOL
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of SALBUTAMOL. Moderate risk. Avoid
SALBUTAMOL [INHALED]
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of SALBUTAMOL [INHALED]. Moderate risk. Avoid
SALICYLAMIDE
Likely interaction of SALICYLAMIDE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
SALIX
Likely interaction of SALIX increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
SALMETEROL XINAFOATE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of SALMETEROL XINAFOATE. Moderate risk. Avoid
SALSALATE
Likely interaction of SALSALATE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
SODIUM SALICYLATE
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of SODIUM SALICYLATE. Moderate risk. May need to avoid combination
SUCRALFATE
Likely interaction of NABUMETONE reducing the ULCER HEALING effect of SUCRALFATE. Moderate risk. Avoid
SULINDAC
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of SULINDAC. Moderate risk. May need to avoid combination
TELMISARTAN
Likely interaction of NABUMETONE increasing the NEPHROTOXICITY of TELMISARTAN. Potential risk. Monitor
TENOXICAM
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of TENOXICAM. Moderate risk. May need to avoid combination
TERBUTALINE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of TERBUTALINE. Moderate risk. Avoid
TERBUTALINE [INHALED]
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of TERBUTALINE [INHALED]. Moderate risk. Avoid
THEOPHYLLINE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of THEOPHYLLINE. Moderate risk. Avoid
TIAPROFENIC ACID
Likely interaction of TIAPROFENIC ACID increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
TINZAPARIN SODIUM
Likely interaction of NABUMETONE increasing the ANTICOAGULANT effect of TINZAPARIN SODIUM. Moderate risk. May need to avoid combination
TOLFENAMIC ACID
Likely interaction of TOLFENAMIC ACID increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. May need to avoid combination
TOLMETIN
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of TOLMETIN. Moderate risk. May need to avoid combination
TRIAMCINOLONE ACETONIDE
Likely interaction of TRIAMCINOLONE ACETONIDE increasing the GASTRIC IRRITANT effect of NABUMETONE. Moderate risk. Monitor
TULOBUTEROL HYDROCHLORIDE
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of TULOBUTEROL HYDROCHLORIDE. Moderate risk. Avoid
VALSARTAN
Likely interaction of NABUMETONE increasing the NEPHROTOXICITY of VALSARTAN. Potential risk. Monitor
ZAFIRLUKAST
Infrequent reports of NABUMETONE reducing the BRONCHODILATOR effect of ZAFIRLUKAST. Moderate risk. Avoid